Trial Profile

A Multicenter, Double-blinded, Randomized, Parallel Design, Phase IIa Clinical Trial to Evaluate the Efficacy, Safety and PK of LCB01-0371 With Vancomycin Versus Vancomycin Monotherapy in Patients With MRSA Bacteremia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Delpazolid (Primary) ; Vancomycin
Indications Bacteraemia; Methicillin-resistant Staphylococcus aureus infections
Focus Therapeutic Use
Sponsors LigaChem Biosciences

13 May 2024 Status changed from recruiting to discontinued because of difficulties in enrolling subjects due to the decrease in patients with MRSA bacteremia .
23 Jan 2024 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
23 Jan 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com